secukinumab 150 mg + secukinumab 300 mg + placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Moderate to Severe Plaque-type Psoriasis
Conditions
Moderate to Severe Plaque-type Psoriasis
Trial Timeline
May 8, 2012 → Oct 24, 2016
NCT ID
NCT01555125About secukinumab 150 mg + secukinumab 300 mg + placebo
secukinumab 150 mg + secukinumab 300 mg + placebo is a phase 3 stage product being developed by Novartis for Moderate to Severe Plaque-type Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT01555125. Target conditions include Moderate to Severe Plaque-type Psoriasis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01806597 | Phase 3 | Completed |
| NCT01555125 | Phase 3 | Completed |
Competing Products
20 competing products in Moderate to Severe Plaque-type Psoriasis